Top Markets
Coin of the day
Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc.

OPNT
Rangering i aksjer #22841
Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical... Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.
Aksjekurs
$20.65
Sist synkronisert: 2023-03-01
Markedsverdi
$82.52M
Endring (1 dag)
-0.58%
Endring (1 år)
0.00%
Land
US
Handel Opiant Pharmaceuticals, Inc. (OPNT)

Kategori

Driftsmargin for Opiant Pharmaceuticals, Inc. (OPNT)
Driftsmargin per 2026 TTM: 0.00%
Ifølge Opiant Pharmaceuticals, Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 0.00%. Ved slutten av 2026 hadde selskapet en driftsmargin på 0.00%.
Historikk for driftsmargin for Opiant Pharmaceuticals, Inc. fra 2026 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
Ikke nok data for de angitte datoene.
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
38.59% -
US
28.81% -
NL
-149.01% -
US
25.72% -
AU
0.00% -
CH
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.